EGFR, KIT, and FLT3 mutants are well known as major oncogenic drivers of lung adenocarcinoma (LAD), gastrointestinal stromal tumor (GIST)/mast cell leukemia (MCL), and acute myeloid leukemia (AML), respectively (3, 4, 5, 6, 7). This evidence concerns the gene KIT and gastrointestinal stromal tumor.